AstraZeneca sales of Covid vaccine triple to $1.2bn in first half of 2021
by Julia Kollewe from Science | The Guardian on (#5MQYA)
Not-for-profit pledge sees British firm's sales revenue fall significantly short of US rival Pfizer
AstraZeneca's Covid-19 vaccine has brought in $1.2bn (900m) in the first half of this year, with sales tripling in the second quarter from the first - but its earnings remained significantly below those of its US rival Pfizer.
Britain's biggest drugmaker revealed that it had generated $894m from Covid-19 vaccine sales in the three months to the end of June, following $275m in the first three months of the year. It has pledged to provide the jab, which it developed with Oxford University, on a not-for-profit basis during this pandemic.
Continue reading...